Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 1998 December;40(4) > Panminerva Medica 1998 December;40(4):269-72

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

PANMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

ORIGINAL ARTICLES  


Panminerva Medica 1998 December;40(4):269-72

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Different reactivity against HCV proteins (Riba 3) according to progression of liver damage

Barbacini I. G., Goldoni E., De Sanctis G. M., Margiotta M. C., Sebastiano D., D’Errico D. A. F., Altavilla N., Magnapera A., Rivanera D.*, Lilli D.*, Ippoliti F.**, Grimaldi F., Mancini C.*, Chircu L. V.

From the Viral Hepatitis Unit, Department of Infectious and Tropical Diseases * Institute of Microbiology ** Department of Experimental Medicine and Pathology University “La Sapienza”, Rome, Italy


PDF  


Background. Aim of the ­study was to ­assess the cor­re­la­tion ­between clin­cal ­stage of HCV-relat­ed liv­er dis­ease and virae­mia to ­immune ­response to dif­fer­ent ­viral anti­gens.
Methods. We con­sid­ered 1330 ­patients ­with HCV chron­ic infec­tion fol­lowed up ­from 6 ­months up to 6 ­years divid­ed ­into two ­groups accord­ing to ­RIBA 3 (Abbott) ­response: ­Group I, 1231 ­patients ­with pos­i­tiv­ity for at ­least two ­bands (83 sub­jects ­with asymp­to­mat­ic infec­tion, 941 ­with chron­ic hep­a­titis, 201 ­with cir­rho­sis and 6 ­with HCC); ­Group II, 99 ­patients ­with pos­i­tiv­ity at ­only one ­band (45 ­with asymp­to­mat­ic infec­tion, 53 ­with chron­ic hep­a­titis and 1 cir­rhot­ic).
Results. We ­noticed a ­major per­cent­age of pos­i­tive ­patients for at ­least ­three ­bands in ­more ­severe clin­i­cal ­forms (90% of chron­ic hep­a­titis or cir­rho­sis ver­sus 60% of asymp­to­mat­ics, p<0.005, χ2 ­test). Moreover we ­noticed a per­cent­age ­increase of pos­i­tiv­ity for anti­bod­ies ­anti-c100 and ­anti-NS5 ­with the pro­gres­sion of liv­er dam­age, sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­enc­es ­between asymp­to­mat­ics and ­patients ­with chron­ic ­forms. We ­also ­observed ­that virae­mia is relat­ed nei­ther to clin­i­cal ­stage nor to dif­fer­ent reac­tiv­ity to ­RIBA 3, ­albeit virae­mia is usu­al­ly detect­ed ­more fre­quent­ly ­among ­patients ­with liv­er dam­age, but unre­lat­ed to dif­fer­ent reac­tiv­ities.
Conclusions. Our ­results ­show a ­clear cor­re­la­tion ­between num­ber of reac­tiv­ities ­towards HCV pro­teins and pro­gres­sion of liv­er dam­age, point­ing out ­that ­immune ­response ­plays a ­direct ­role in the ­long-­term out­come of HCV infec­tion.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail